The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms.
Thiele J, Kvasnicka HM, Orazi A, Gianelli U, Gangat N, Vannucchi AM, Barbui T, Arber DA, Tefferi A.
Am J Hematol. 2023 Jan;98(1):166-179. doi: 10.1002/ajh.26751. Epub 2022 Oct 14.
Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
Palomo L, Meggendorfer M, Hutter S, Twardziok S, Ademà V, Fuhrmann I, Fuster-Tormo F, Xicoy B, Zamora L, Acha P, Kerr CM, Kern W, Maciejewski JP, Solé F, Haferlach C, Haferlach T.
Blood. 2020 Oct 15;136(16):1851-1862. doi: 10.1182/blood.2019004229.
Postoperative bone metastases of unclassified renal cell carcinoma.
Ma P, Yu C, Cui J, Li S.
Asian J Surg. 2024 Jan;47(1):602-603. doi: 10.1016/j.asjsur.2023.09.127. Epub 2023 Oct 8.
Myeloproliferative Neoplasms.
Thapa B, Fazal S, Parsi M, Rogers HJ.
2023 Aug 8. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2026 Jan–.
Role of allo-HCT in "nonclassical" MPNs and MDS/MPNs: recommendations from the PH&G Committee and the CMWP of the EBMT.
Polverelli N, Hernández-Boluda JC, Onida F, Gurnari C, Raj K, Czerw T, Kenyon M, Robin M, Sockel K, Ruggeri A, Sánchez-Ortega I, Arber DA, Arcaini L, Duarte FB, Battipaglia G, Chalandon Y, Ciceri F, Cross NCP, Drozd-Sokolowska J, Funke V, Gagelmann N, Gangat N, Gotlib J, Guglielmelli P, Harrison C, Hobbs G, Jain T, Khoury JD, Kiladjian JJ, Kröger N, Malcovati L, Martino M, Mesa R, Orazi A, Padron E, Palandri F, Passamonti F, Patnaik MM, Pemmaraju N, Radia DH, Reiter A, Russo D, Scheid C, Tefferi A, Vannucchi AM, Wiseman DH, Yakoub-Agha I, McLornan DP.
Blood. 2025 May 29;145(22):2561-2573. doi: 10.1182/blood.2024028000.
Decision tree-based data mining approach for the evaluation of survival in primary malignant bone tumors: A surveillance, epidemiology and end results database study.
Yapar D, Yapar A, Tokgöz MA, Bilge U.
J Orthop Surg (Hong Kong). 2023 May-Aug;31(2):10225536231189780. doi: 10.1177/10225536231189780.
Rare Case of BCOR::CCNB3 Sarcoma of Bone.
Arai Y, Yazawa Y, Torigoe T, Imanishi J, Motoi T, Yasuda M, Tanaka R, Fukushima T, Watanabe A, Ohta A, Shimizu Y, Kadono Y, Saita K.
Am J Case Rep. 2023 Mar 14;24:e938158. doi: 10.12659/AJCR.938158.
EWSR1::ATF1 fusions characterize a group of extra-abdominal epithelioid and round cell mesenchymal neoplasms, phenotypically overlapping with sclerosing epithelioid fibrosarcomas, and intra-abdominal FET::CREB fusion neoplasms.
Rekhi B, Dermawan JK, Fritchie KJ, Zimpfer A, Mohammad TM, Ali FS, Nandy K, Zou Y, Stoehr R, Agaimy A.
Virchows Arch. 2024 Dec;485(6):995-1005. doi: 10.1007/s00428-024-03879-5. Epub 2024 Jul 20.
Redefining radiologic responses in high-risk soft-tissue sarcomas treated with neoadjuvant chemotherapy: final results of ISG-STS 1001, a randomized clinical trial.
Vanzulli A, Vigorito R, Buonomenna C, Palmerini E, Quagliuolo V, Broto JM, Lopez Pousa A, Grignani G, Brunello A, Blay JY, Diaz Beveridge R, Ferraresi V, Lugowska I, Pizzamiglio S, Verderio P, Duroni V, Fontana V, Donati DM, Palassini E, Bianchi G, Bertuzzi A, Buonadonna A, Pasquali S, Dei Tos AP, Casali PG, Morosi C, Stacchiotti S, Gronchi A.
ESMO Open. 2025 Mar;10(3):104299. doi: 10.1016/j.esmoop.2025.104299. Epub 2025 Mar 7.
Response-Adapted Ultralow-Dose Radiation Therapy for Orbital Indolent B-Cell Lymphoma: A Phase 2 Nonrandomized Controlled Trial.
Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, Westin J, Neelapu S, Rodriguez MA, Lee HJ, Wang M, Flowers C, Feng L, Esmaeli B.
JAMA Oncol. 2024 Sep 1;10(9):1195-1203. doi: 10.1001/jamaoncol.2024.2112.
